LDS/Medical Tests/MYL3 Gene Mutation Analysis

MYL3 Gene Mutation Analysis

The MYL3 gene is located in the short (p) arm of chromosome 3 at position 21 and encodes for myosin essential light chain 3 (ELC3) also known as the ventricular/cardiac isoform and ventricular/cardiac ELC. ELC3 is a 21.9 kDa protein composed of 195 amino acids and is the myosin light chain isoform present in cardiac muscle where it functions to modulate cardiac muscle contraction. Although ELC3 is a member of the EF-hand superfamily of proteins, it does not bind calcium at physiological levels. Due to the presence of positively charged lysine residues the N-terminal region is functionally unique and is able to bind actin and contribute to force production.

Mutations in MYL3 have been identified as a cause of familial hypertrophic cardiomyopathy that is associated with mid-left ventricular chamber hypertrophy. Inherited HCM is typically transmitted as an autosomal dominant heart disorder characterized by unexplained left ventricular (LV) hypertrophy (thickening) associated with non-dilated ventricular chambers. Pathological features include myocardial fiber hypertrophy, disorganized myocardial cells, interstitial fibrosis and thickened intra-myocardial coronary vessels. The majority of HCM patients are asymptomatic. Only about 25% develop symptom such as dyspnea, syncope, collapse, palpitations, and chest pain. The disorder has inter- and intra-familial variability ranging from benign cases to malignant forms with a high risk of cardiac failure and sudden cardiac death.

HCM is the most common cause of sudden cardiac death in young people and has a prevalence of 1:500 in the general adult population. The majority of the mutations in HCM are missense, insertion/deletion and frame-shift mutations. To date, nine HCM causing mutations to have been described in MYL3. Mutations in MYL3 account for < 3% of cases of inherited HCM.

  • As an aid in diagnosis of familial hypertrophic cardiomyopathy and dilated cardiomyopathy
  • Carrier screening for relatives and those with the family history
  • Prenatal carrier screening for those with the family history
Mutations or pathogenic variant in MYL3gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutations analyzed (No pathogenic variant or mutation detected)

Sequence analysis by targeted next generation sequencing, MYL3 gene-targeted deletion/duplication analysis by quantitative multiplex PCR, long-range PCR, multiplex ligation dependent probe amplification (MLPA).

Whole blood (EDTA). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Creatine kinase (CK), CK-MB, lactate dehydrogenase (LDH), troponin T, myosin light chain-1 (MLC-1), electrocardiogram, chest X-ray, exercise stress echocardiography, cardiac catheterization and magnetic resonance imaging (MRI).
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login